Industry Perspective: Illuccix® for Gallium-68-PSMA-11 PET Imaging of Prostate Cancer
In this Industry Perspective, supported by Telix Pharmaceuticals, Bradley Fehrenbach, MD, MBA, presents Illuccix® for 68Ga-PSMA-11 PET imaging of prostate cancer. Dr. Fehrenbach begins by listing the FDA-approved indications for the use of Illuccix® during initial prostate cancer staging, after biochemical recurrence of prostate cancer, and before treating mCRPC.
Dr. Fehrenbach reviews data supporting the high diagnostic value, reproducibility, and accuracy of Illuccix®. He presents studies demonstrating its high true-positive rate, its ability to detect clinically significant disease when PSA level is as low as 0.02 ng/ml, and high inter-reader agreement.
Dr. Fehrenback concludes by listing the clinical benefits and practical accessibility of Gallium radiotracers for PET scans. At the conclusion of his presentation, he briefly answers questions posed to him by the Program Chair.
Read More